Register Login

Corvus Pharmaceuticals Inc (CRVS)

(90% Positive) Corvus Pharmaceuticals Inc (CRVS) Announces Enrollment Update for soquelitinib Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 6:40 p.m.

    📋 Corvus Pharmaceuticals Inc (CRVS) - Clinical Trial Update

    Filing Date: 2026-01-20

    Accepted: 2026-01-20 07:13:09

    Event Type: Clinical Trial Update

    Event Details:

    Corvus Pharmaceuticals Inc (CRVS) Announces Clinical Trial Update Corvus Pharmaceuticals Inc (CRVS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: soquelitinib
    • Clinical Stage: Clinical Trial, Phase 1
    • Collaboration: EASI

    🔬 Clinical Development Pipeline (Corvus Pharmaceuticals Inc):

    Product Type Development Stage Therapeutic Area Source
    Placebo + SOC DRUG Phase PHASE3 Covid-19 ClinicalTrials.gov
    Soquelitinib DRUG Phase PHASE1 Atopic Dermatitis ClinicalTrials.gov
    CPI-818 DRUG Phase PHASE1 T-cell Lymphoma ClinicalTrials.gov
    HU6 DRUG Phase PHASE1 Overweight ClinicalTrials.gov
    CPI-444 Tablets DRUG Phase PHASE1 Healthy Subjects ClinicalTrials.gov
    CPI-444 Capsules DRUG Phase PHASE1 Healthy Subjects ClinicalTrials.gov
    Ciforadenant DRUG Phase PHASE1 Renal Cell Cancer ClinicalTrials.gov
    Ciforadenant + atezolizumab DRUG Phase PHASE1 Renal Cell Cancer ClinicalTrials.gov
    Standard of Care OTHER Phase PHASE1 COVID-19 ClinicalTrials.gov
    CPI-006 DRUG Phase PHASE1 COVID-19 ClinicalTrials.gov
    daratumumab DRUG Phase PHASE1 Multiple Myeloma ClinicalTrials.gov
    CPI-006 1 mg/kg + SOC DRUG Phase PHASE3 Covid-19 ClinicalTrials.gov
    CPI-006 2 mg/kg + SOC DRUG Phase PHASE3 Covid-19 ClinicalTrials.gov
    HU6 Capsule DRUG Phase PHASE1 Obese ClinicalTrials.gov
    HU6 Tablet DRUG Phase PHASE1 Obese ClinicalTrials.gov
    Placebo DRUG Phase PHASE2 NASH - Nonalcoholic Steatohepatitis ClinicalTrials.gov
    [14C]-HU6 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    CPI-006 + pembrolizumab DRUG Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov
    CPI-006 + ciforadenant DRUG Phase PHASE1 Non-Small Cell Lung Cancer ClinicalTrials.gov
    HU6 150 mg Capsules x 3 (Total dose = 450 mg) DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    HU6 450 mg Tablet DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Pralatrexate DRUG Phase PHASE3 Peripheral T-Cell Lymphoma, Not Otherwise Specified ClinicalTrials.gov
    Belinostat DRUG Phase PHASE3 Peripheral T-Cell Lymphoma, Not Otherwise Specified ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Corvus Pharmaceuticals Inc
    • Ticker Symbol: CRVS

Search

News categories